iShares MSCI Singapore ETF vs Kymera Therapeutics Inc. Common Stock — how do they compare? iShares MSCI Singapore ETF trades at $31.22 (market cap $1.23B), while Kymera Therapeutics Inc. Common Stock trades at $105.11 (market cap $8.87B). The key difference: Kymera Therapeutics Inc. Common Stock is far larger — about 7.2× iShares MSCI Singapore ETF's market cap, and Kymera Therapeutics Inc. Common Stock is trading nearer its 52-week high, iShares MSCI Singapore ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Singapore ETF for 47 Days and Kymera Therapeutics Inc. Common Stock for 0 Days on average.
| EWS | KYMR | |
|---|---|---|
Market Cap | $1.23B | $8.87B |
Volume | 3,153,173 | 779,107 |
Sector | Broad Market / Factor | Health |
52-Week High | $34.57 | $127.31 |
52-Week Low | $26.71 | $55.80 |
Typical Hold Time | 47 Days | 0 Days |
Enterprise Value | — | $8.26B |
Signals from Pluang's Aura AI — not financial advice
EWS, the iShares MSCI Singapore ETF, trades at $31.54, down slightly by 0.03% on the day. Technical indicators are mixed, with moving averages signaling a bearish trend while oscillators suggest potential oversold conditions. The ETF recently hit a 52-week high, driven by Singapore's strong economic growth and AI momentum. Institutional interest is positive, with Amundi increasing its stake by 4.8% as of its latest 13F filing.
The outlook for EWS is cautiously optimistic, supported by Singapore's resilient economy and institutional inflows. Key risks include stretched valuations after the multi-year rally and sensitivity to regional economic shifts. Investors should weigh the strong momentum against potential pullbacks in a high-valuation environment.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
EWS tracks the MSCI Singapore 25/50 Index, providing targeted exposure to large and mid-cap companies in Singapore. It is heavily weighted toward the financial, industrial, and real estate sectors, serving as a liquid tool for accessing Singapore's stable, dividend-oriented developed economy.
Read more on EWS →Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →